These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 31915870)
41. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. Alikhan A; Sayed C; Alavi A; Alhusayen R; Brassard A; Burkhart C; Crowell K; Eisen DB; Gottlieb AB; Hamzavi I; Hazen PG; Jaleel T; Kimball AB; Kirby J; Lowes MA; Micheletti R; Miller A; Naik HB; Orgill D; Poulin Y J Am Acad Dermatol; 2019 Jul; 81(1):91-101. PubMed ID: 30872149 [TBL] [Abstract][Full Text] [Related]
42. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Zouboulis CC; Desai N; Emtestam L; Hunger RE; Ioannides D; Juhász I; Lapins J; Matusiak L; Prens EP; Revuz J; Schneider-Burrus S; Szepietowski JC; van der Zee HH; Jemec GB J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):619-44. PubMed ID: 25640693 [TBL] [Abstract][Full Text] [Related]
43. Lipocalin-2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Wolk K; Wenzel J; Tsaousi A; Witte-Händel E; Babel N; Zelenak C; Volk HD; Sterry W; Schneider-Burrus S; Sabat R Br J Dermatol; 2017 Nov; 177(5):1385-1393. PubMed ID: 28256718 [TBL] [Abstract][Full Text] [Related]
44. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. Jemec GB; Wendelboe P J Am Acad Dermatol; 1998 Dec; 39(6):971-4. PubMed ID: 9843011 [TBL] [Abstract][Full Text] [Related]
45. Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy. Vural S; Gündoğdu M; Akay BN; Boyvat A; Erdem C; Koçyiğit P; Bostancı S; Sanli H; Kundakci N Dermatol Ther; 2019 Sep; 32(5):e13003. PubMed ID: 31237104 [TBL] [Abstract][Full Text] [Related]
46. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. Fischer AH; Haskin A; Okoye GA J Am Acad Dermatol; 2017 Feb; 76(2):309-313.e2. PubMed ID: 27742173 [TBL] [Abstract][Full Text] [Related]
47. [Acne inversa/hidradenitis suppurativa: A challenge for the future]. Sabat R Hautarzt; 2017 Dec; 68(12):994-998. PubMed ID: 29110042 [TBL] [Abstract][Full Text] [Related]
57. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa. Yao Y; Thomsen SF Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469692 [TBL] [Abstract][Full Text] [Related]
58. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic. Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899 [No Abstract] [Full Text] [Related]
59. Hidradenitis suppurativa: a review with a focus on treatment data. Barlev D; Eisen DB; Alikhan A Skin Therapy Lett; 2015; 20(4):1-8. PubMed ID: 26382710 [TBL] [Abstract][Full Text] [Related]